- •
Corticosteroids are almost universally effective for the treatment of sarcoidosis. The treatment of sarcoidosis is indicated if the disease causes a dangerous health situation or significantly impairs the patient's quality of life.
- •
Treatment should not be based on biomarkers of active granulomatous inflammation.
- •
Pulmonary sarcoidosis can usually be adequately treated with modest doses of corticosteroids.
- •
It is unusual for patients to be refractory to corticosteroid therapy. Alternative medications
Corticosteroids in Sarcoidosis
Section snippets
Key points
Indications to treat sarcoidosis
There are 2 indications for the treatment of sarcoidosis: (1) the development of a dangerous health situation; and (2) significant worsening of quality of life. Table 1 lists several situations of danger resulting from sarcoidosis. Note that many of these relate to the development of fibrosis, which, unlike active granulomatous inflammation, is not corticosteroid responsive. Furthermore, most of the entities listed in Table 1 are rare manifestations of sarcoidosis. Therefore, the overwhelmingly
General approach to the treatment of sarcoidosis with corticosteroids
Corticosteroids are the initial drug of choice for the treatment of most forms of sarcoidosis because they are almost universally effective and a significant response is quickly observed, usually in a matter of a few weeks or less.10 Alternative antisarcoidosis therapies, including methotrexate11 antimalarials,12 and others,13 usually require several months to achieve a meaningful response. In addition, most alternative antisarcoidosis medications when used as monotherapy are effective as sole
Pulmonary Sarcoidosis
A Delphi study of sarcoidosis experts reached a consensus that corticosteroids are the drug of choice for the treatment of pulmonary sarcoidosis.23 The American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Diseases consensus statement recommends a daily prednisone equivalent of 20 to 40 mg for the initial treatment of pulmonary sarcoidosis.24 It is recommended that this dose be continued for at least 1 to 3 months and then tapered to a
Summary
Corticosteroids are the drug of choice for the treatment of sarcoidosis. Because of the toxicity of corticosteroids and other antisarcoidosis medications, therapy should only be considered when sarcoidosis causes a dangerous/potentially dangerous health situation or significantly affects the patient’s quality of life. Topical/local therapy should be considered whenever possible to minimize the risk of corticosteroid toxicity. When systemic therapy is required, patients should be aggressively
References (103)
- et al.
Respiratory muscle strength, lung function, and dyspnea in patients with sarcoidosis
Chest
(2001) The treatment of pulmonary sarcoidosis
Respir Med
(2012)- et al.
Outcome in sarcoidosis. The relationship of relapse to corticosteroid therapy
Chest
(1997) - et al.
Efficacy of short-course, low-dose corticosteroid therapy for acute pulmonary sarcoidosis exacerbations
Am J Med Sci
(2010) - et al.
Steroid-sparing alternative treatments for sarcoidosis
Clin Chest Med
(1997) - et al.
A randomized, investigator-masked, double-blind, placebo-controlled trial on thalidomide in severe cutaneous sarcoidosis
Chest
(2014) - et al.
The potential additional benefit of infliximab in patients with chronic pulmonary sarcoidosis already receiving corticosteroids: a retrospective analysis from a randomized clinical trial
Respir Med
(2014) - et al.
Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study
Respir Med
(2010) An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment
Chest
(1999)Sarcoidosis
Mayo Clin Proc
(1995)
Oral prednisolone followed by inhaled budesonide in newly diagnosed pulmonary sarcoidosis: a double-blind, placebo-controlled multicenter study. Finnish Pulmonary Sarcoidosis Study Group
Chest
Early treatment of stage II sarcoidosis improves 5-year pulmonary function
Chest
Incidence and prognostic significance of myocardial late gadolinium enhancement in patients with sarcoidosis without cardiac manifestation
Chest
Management of cardiac sarcoidosis in the United States: a Delphi study
Chest
Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone
Am J Cardiol
Chronic cutaneous lesions of sarcoidosis
Clin Dermatol
Cutaneous sarcoidosis therapy updated
J Am Acad Dermatol
Intralesional corticosteroids
J Am Acad Dermatol
Treatment of cutaneous sarcoidosis using phonophoresis
J Am Acad Dermatol
Cutaneous sarcoidosis: prognosis and treatment
Clin Dermatol
Sarcoidosis: a comprehensive review and update for the dermatologist: part I. Cutaneous disease
J Am Acad Dermatol
Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas
J Am Acad Dermatol
Evidence-based therapy for cutaneous sarcoidosis
Clin Dermatol
The treatment of lupus pernio: results of 116 treatment courses in 54 patients
Chest
Prognosticators for visual outcome in sarcoid uveitis
Ophthalmology
Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients
Ophthalmology
Methotrexate treatment for sarcoid-associated panuveitis
Ophthalmology
Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation
Ophthalmology
Neurosarcoidosis: clinical manifestations, diagnosis and treatment
Presse Med
Neurosarcoidosis: a personal perspective based on the study of 37 patients
Chest
Neurosarcoidosis treated with mycophenolate mofetil: two cases
Rev Neurol (Paris)
Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen
Chest
Infliximab therapy rescues cyclophosphamide failure in severe central nervous system sarcoidosis
Respir Med
Lofgren's syndrome revisited: a study of 186 patients
Am J Med
Musculoskeletal and other extrapulmonary disorders in sarcoidosis
Best Pract Res Clin Rheumatol
Endpoints for clinical trials of sarcoidosis
Sarcoidosis Vasc Diffuse Lung Dis
Presentation of sarcoidosis and outcome of pulmonary changes
Dan Med Bull
Two year prognosis of sarcoidosis: the ACCESS experience
Sarcoidosis Vasc Diffuse Lung Dis
The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States
Sarcoidosis Vasc Diffuse Lung Dis
Determining the cause of pulmonary granulomas: a multidimensional process
Respirology
The late follow-up of chronic sarcoid patients previously treated with corticosteroids
Sarcoidosis Vasc Diffuse Lung Dis
Prolonged use of methotrexate for sarcoidosis
Arch Intern Med
Randomized trial of prolonged chloroquine therapy in advanced pulmonary sarcoidosis
Am J Respir Crit Care Med
The use of tetracyclines for the treatment of sarcoidosis
Arch Dermatol
Corticosteroids for pulmonary sarcoidosis
Cochrane Database Syst Rev
A concise review of pulmonary sarcoidosis
Am J Respir Crit Care Med
Effects of sarcoid and steroids on angiotensin-converting enzyme
Am Rev Respir Dis
67Ga scanning for assessment of disease activity and therapy decisions in pulmonary sarcoidosis in comparison to chest radiography, serum ACE and blood T-lymphocytes
Eur J Nucl Med
Assessing pulmonary disease and response to therapy: which test?
Semin Respir Crit Care Med
Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis
Eur Respir J
Cited by (46)
Anti-inflammatory Therapy for Sarcoidosis
2024, Clinics in Chest MedicineHealth-Related Quality of Life Assessment in Sarcoidosis
2024, Clinics in Chest MedicineTetrastigma hemsleyanum alleviates sarcoidosis through metabolomic regulation and Th17/Treg immune homeostasis
2022, Journal of Functional FoodsCitation Excerpt :Consequently, the clinical manifestation of sarcoidosis is variable which depends on the severity of organ involvement. As a progressive chronic disease, the etiology and pathogenesis of sarcoidosis is complex, which brings unprecedented challenge to the prevention and treatment of sarcoidosis (Judson, 2016). As the therapy for sarcoidosis treatment, corticosteroid and non-glucocorticoid can alleviate patients’ symptoms in the short term.
Corticosteroid refractory sarcoidosis
2020, Respiratory MedicineSarcoidosis of the central nervous system: Safety and efficacy of treatment, and experience of biological therapies
2020, Clinical Neurology and Neurosurgery